The Beauty Health Company (NASDAQ:SKIN) Receives $6.50 Average Target Price from Brokerages

The Beauty Health Company (NASDAQ:SKIN) has received an average recommendation of “Reduce” from the twelve analysts that are presently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $6.50.

SKIN has been the subject of a number of recent research reports. DA Davidson reaffirmed a “buy” rating and set a $5.00 price target on shares of Beauty Health in a research report on Friday, March 15th. Piper Sandler reaffirmed an “underweight” rating and set a $3.00 price target (up previously from $2.00) on shares of Beauty Health in a research report on Wednesday, March 13th. TD Cowen upped their price target on Beauty Health from $2.50 to $4.00 and gave the stock a “market perform” rating in a research report on Wednesday, March 13th. Stifel Nicolaus reaffirmed a “hold” rating and set a $4.00 price target (up previously from $3.00) on shares of Beauty Health in a research report on Wednesday, March 13th. Finally, Canaccord Genuity Group upped their price target on Beauty Health from $3.00 to $4.00 and gave the stock a “hold” rating in a research report on Thursday, March 14th.

Institutional Investors Weigh In On Beauty Health

Large investors have recently made changes to their positions in the stock. Kestra Private Wealth Services LLC lifted its holdings in Beauty Health by 40.8% during the 3rd quarter. Kestra Private Wealth Services LLC now owns 15,887 shares of the company’s stock valued at $96,000 after purchasing an additional 4,600 shares during the last quarter. M&T Bank Corp lifted its holdings in Beauty Health by 6.8% during the 3rd quarter. M&T Bank Corp now owns 125,706 shares of the company’s stock valued at $756,000 after purchasing an additional 8,036 shares during the last quarter. Levin Capital Strategies L.P. lifted its holdings in Beauty Health by 100.0% during the 3rd quarter. Levin Capital Strategies L.P. now owns 20,000 shares of the company’s stock valued at $120,000 after purchasing an additional 10,000 shares during the last quarter. Raymond James & Associates acquired a new stake in Beauty Health during the 4th quarter valued at $31,000. Finally, Raymond James Financial Services Advisors Inc. acquired a new stake in Beauty Health during the 4th quarter valued at $31,000. Institutional investors and hedge funds own 93.26% of the company’s stock.

Beauty Health Price Performance

NASDAQ SKIN opened at $3.22 on Friday. The business has a 50 day simple moving average of $3.66 and a 200 day simple moving average of $3.43. Beauty Health has a 52-week low of $1.35 and a 52-week high of $13.06. The company has a debt-to-equity ratio of 12.43, a quick ratio of 5.28 and a current ratio of 6.07. The stock has a market cap of $397.44 million, a price-to-earnings ratio of -4.18 and a beta of 1.01.

Beauty Health (NASDAQ:SKIN) last posted its earnings results on Tuesday, March 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. Beauty Health had a negative return on equity of 18.85% and a negative net margin of 25.65%. The business had revenue of $96.80 million during the quarter, compared to analysts’ expectations of $87.22 million. During the same period in the prior year, the business earned $0.03 EPS. Beauty Health’s revenue for the quarter was down 1.3% compared to the same quarter last year. Analysts anticipate that Beauty Health will post -0.1 earnings per share for the current fiscal year.

About Beauty Health

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.